Basilea Pharmaceutica (BSLN) Investor presentation summary

Company overview and leadership

• Profitable Swiss biopharmaceutical firm focused on anti-infectives, spun off from Roche in 2000, with about 190 employees and listed on SIX Swiss Exchange.

• Executive team with deep industry experience across R&D, clinical, and commercial functions.

Strategic focus and business model

• Concentrates on severe bacterial and fungal diseases with high unmet medical need, targeting resistance and lack of effective therapies.

• Asset-light, capital-efficient model leveraging partnerships, non-dilutive funding, and limited upfront costs.

• Generates revenue through product sales, royalties, and milestone payments, with global commercial partners.

Market drivers and unmet needs

• Rising incidence of invasive infections due to aging, immunosuppression, medical advances, resistance, and climate change.

• Focus on pathogens with limited treatment options and growing resistance, such as Candida, Aspergillus, and multidrug-resistant bacteria.